Andersen-Tawil syndrome: deep phenotyping reveals significant cardiac and neuromuscular morbidity.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
30 06 2022
Historique:
received: 08 05 2021
revised: 21 09 2021
accepted: 13 12 2021
pubmed: 18 12 2021
medline: 6 7 2022
entrez: 17 12 2021
Statut: ppublish

Résumé

Andersen-Tawil syndrome is a neurological channelopathy caused by mutations in the KCNJ2 gene that encodes the ubiquitously expressed Kir2.1 potassium channel. The syndrome is characterized by episodic weakness, cardiac arrythmias and dysmorphic features. However, the full extent of the multisystem phenotype is not well described. In-depth, multisystem phenotyping is required to inform diagnosis and guide management. We report our findings following deep multimodal phenotyping across all systems in a large case series of 69 total patients, with comprehensive data for 52. As a national referral centre, we assessed point prevalence and showed it is higher than previously reported, at 0.105 per 100 000 population in England. While the classical phenotype of episodic weakness is recognized, we found that a quarter of our cohort have fixed myopathy and 13.5% required a wheelchair or gait aid. We identified frequent fat accumulation on MRI and tubular aggregates on muscle biopsy, emphasizing the active myopathic process underpinning the potential for severe neuromuscular disability. Long exercise testing was not reliable in predicting neuromuscular symptoms. A normal long exercise test was seen in five patients, of whom four had episodic weakness. Sixty-seven per cent of patients treated with acetazolamide reported a good neuromuscular response. Thirteen per cent of the cohort required cardiac defibrillator or pacemaker insertion. An additional 23% reported syncope. Baseline electrocardiograms were not helpful in stratifying cardiac risk, but Holter monitoring was. A subset of patients had no cardiac symptoms, but had abnormal Holter monitor recordings which prompted medication treatment. We describe the utility of loop recorders to guide management in two such asymptomatic patients. Micrognathia was the most commonly reported skeletal feature; however, 8% of patients did not have dysmorphic features and one-third of patients had only mild dysmorphic features. We describe novel phenotypic features including abnormal echocardiogram in nine patients, prominent pain, fatigue and fasciculations. Five patients exhibited executive dysfunction and slowed processing which may be linked to central expression of KCNJ2. We report eight new KCNJ2 variants with in vitro functional data. Our series illustrates that Andersen-Tawil syndrome is not benign. We report marked neuromuscular morbidity and cardiac risk with multisystem involvement. Our key recommendations include proactive genetic screening of all family members of a proband. This is required, given the risk of cardiac arrhythmias among asymptomatic individuals, and a significant subset of Andersen-Tawil syndrome patients have no (or few) dysmorphic features or negative long exercise test. We discuss recommendations for increased cardiac surveillance and neuropsychometry testing.

Identifiants

pubmed: 34919635
pii: 6469017
doi: 10.1093/brain/awab445
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2108-2120

Subventions

Organisme : Medical Research Council
ID : G0902001
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V037838/1
Pays : United Kingdom

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Vinojini Vivekanandam (V)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Roope Männikkö (R)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Iwona Skorupinska (I)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Louise Germain (L)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Belinda Gray (B)

Cardiovascular Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, London, UK.

Sarah Wedderburn (S)

West of Scotland Regional Genetics Service, Queen Elizabeth University Hospital, Glasgow, UK.

Damian Kozyra (D)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Richa Sud (R)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Natalie James (N)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Sarah Holmes (S)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Konstantinos Savvatis (K)

Cardiology Department, St Bartholomew's Hospital, London, UK.

Doreen Fialho (D)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Ashirwad Merve (A)

Department of Neuropathology, National Hospital for Neurology and Neurosurgery, London, UK.

Jatin Pattni (J)

Neuropsychology, National Hospital for Neurology and Neurosurgery, London, UK.

Maria Farrugia (M)

West of Scotland Regional Genetics Service, Queen Elizabeth University Hospital, Glasgow, UK.

Elijah R Behr (ER)

Cardiovascular Clinical Academic Group, St. George's, University of London and St. George's University Hospitals NHS Foundation Trust, London, UK.

Chiara Marini-Bettolo (C)

John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Michael G Hanna (MG)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Emma Matthews (E)

Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
Atkinson-Morley Neuromuscular Centre, Department of Neurology, St George's University Hospitals NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH